Wolfram Carius, EVP Pharmaceuticals, Head of Cell & Gene Therapy (Bayer)
December 2, 2020 07:26 AM ESTUpdated 11:10 AM
Pharma
Cell/Gene Tx

Bay­er con­tin­ues its cell and gene ther­a­py push, en­velop­ing dif­fer­ent projects un­der one strate­gic roof while hunt­ing new deals

Max Gelman

Senior Editor

Rough­ly five weeks af­ter buy­ing out Askle­pios — al­so known as AskBio — for up to $4 bil­lion, Bay­er is ham­mer­ing home its fo­cus on cell …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Blue­bird bio to sell to in­vest­ment funds af­ter strug­gling to make mon­ey from gene ther­a­pies

CBER's deputy di­rec­tor de­parts as staff shake­up con­tin­ues

Eli Lil­ly stock­piles $548M of oral weight loss drug ahead of launch

Will CRISPR mat­ter?

FDA ap­proves first drug to treat ul­tra-rare lipid stor­age dis­ease

sponsored

Trust­ed pro­tec­tion: Why the cur­rent meningo­coc­cal vac­ci­na­tion sched­ule shouldn’t change with­out strong ev­i­dence

A service from the Financial Times